Cargando…

Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.

Seven hundred and eighty-six subjects spontaneously referring to our Center performed two guaiac (Rehydrated Hemoccult II (R.HO), and Hemoccult Sensa (HO S.)), and two immunochemical (OC Hemodia (Hdia) and Hemeselect (Hsel)) faecal occult blood tests on three consecutive faecal determinations. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Castiglione, G., Grazzini, G., Ciatto, S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977762/
https://www.ncbi.nlm.nih.gov/pubmed/1616868
_version_ 1782135331494035456
author Castiglione, G.
Grazzini, G.
Ciatto, S.
author_facet Castiglione, G.
Grazzini, G.
Ciatto, S.
author_sort Castiglione, G.
collection PubMed
description Seven hundred and eighty-six subjects spontaneously referring to our Center performed two guaiac (Rehydrated Hemoccult II (R.HO), and Hemoccult Sensa (HO S.)), and two immunochemical (OC Hemodia (Hdia) and Hemeselect (Hsel)) faecal occult blood tests on three consecutive faecal determinations. The positivity rates of 3 day R.HO, HO S., Hdia, and Hsel were 4.8%, 5.6%, 8.4% and 11.2% respectively. One hundred and thirty-five of the 150 subjects with at least one positive test completed the diagnostic work-up. Cancer was detected in three subjects and adenomas in 15. Three-day specificity estimates of R.HO, HO S., Hdia and Hsel in the overall series were 96.1%, 96.0%, 93.8% and 91.2% respectively, the differences between guaiac and immunochemical tests being significant. Corresponding values of specificity as determined on the first faecal sample only in the overall series were 98.1%, 98.3%, 96.1% and 94.9% respectively. No significant difference in specificity is evident when 3-day guaiac tests are compared to 1-day immunochemical ones. Three-day immunochemical testing is not recommended for screening purposes due to its very low specificity. Nevertheless, 1-day immunochemical testing is almost as specific as 3-day guaiac testing. A preliminary estimate of colonic neoplasms detection rates shows no difference as well. The benefit of 1-day testing on screening acceptability is evident, but the impact on sensitivity should be evaluated in a screening situation with a proper study design and a larger sample size.
format Text
id pubmed-1977762
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19777622009-09-10 Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening. Castiglione, G. Grazzini, G. Ciatto, S. Br J Cancer Research Article Seven hundred and eighty-six subjects spontaneously referring to our Center performed two guaiac (Rehydrated Hemoccult II (R.HO), and Hemoccult Sensa (HO S.)), and two immunochemical (OC Hemodia (Hdia) and Hemeselect (Hsel)) faecal occult blood tests on three consecutive faecal determinations. The positivity rates of 3 day R.HO, HO S., Hdia, and Hsel were 4.8%, 5.6%, 8.4% and 11.2% respectively. One hundred and thirty-five of the 150 subjects with at least one positive test completed the diagnostic work-up. Cancer was detected in three subjects and adenomas in 15. Three-day specificity estimates of R.HO, HO S., Hdia and Hsel in the overall series were 96.1%, 96.0%, 93.8% and 91.2% respectively, the differences between guaiac and immunochemical tests being significant. Corresponding values of specificity as determined on the first faecal sample only in the overall series were 98.1%, 98.3%, 96.1% and 94.9% respectively. No significant difference in specificity is evident when 3-day guaiac tests are compared to 1-day immunochemical ones. Three-day immunochemical testing is not recommended for screening purposes due to its very low specificity. Nevertheless, 1-day immunochemical testing is almost as specific as 3-day guaiac testing. A preliminary estimate of colonic neoplasms detection rates shows no difference as well. The benefit of 1-day testing on screening acceptability is evident, but the impact on sensitivity should be evaluated in a screening situation with a proper study design and a larger sample size. Nature Publishing Group 1992-06 /pmc/articles/PMC1977762/ /pubmed/1616868 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Castiglione, G.
Grazzini, G.
Ciatto, S.
Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title_full Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title_fullStr Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title_full_unstemmed Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title_short Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
title_sort guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977762/
https://www.ncbi.nlm.nih.gov/pubmed/1616868
work_keys_str_mv AT castiglioneg guaiacandimmunochemicaltestsforfaecaloccultbloodincolorectalcancerscreening
AT grazzinig guaiacandimmunochemicaltestsforfaecaloccultbloodincolorectalcancerscreening
AT ciattos guaiacandimmunochemicaltestsforfaecaloccultbloodincolorectalcancerscreening